Minimum manufacturing costs, national prices and estimated global availability of new repurposed therapies for COVID-19
View ORCID ProfileJunzheng Wang, Jacob Levi, Leah Ellis, Andrew Hill
doi: https://doi.org/10.1101/2021.06.01.21258147
Junzheng Wang
1Faculty of Medicine, Imperial College London
Jacob Levi
2Department of Intensive Care, University College London Hospital, University College London Hospitals NHS Foundation Trust
Leah Ellis
1Faculty of Medicine, Imperial College London
Andrew Hill
3Department of Pharmacology and Therapeutics, University of Liverpool
![Loading Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Data Availability
Data used for this study is available upon request to the authors.
Posted July 28, 2021.
Minimum manufacturing costs, national prices and estimated global availability of new repurposed therapies for COVID-19
Junzheng Wang, Jacob Levi, Leah Ellis, Andrew Hill
medRxiv 2021.06.01.21258147; doi: https://doi.org/10.1101/2021.06.01.21258147
Subject Area
Subject Areas
- Addiction Medicine (344)
- Allergy and Immunology (666)
- Anesthesia (181)
- Cardiovascular Medicine (2635)
- Dermatology (223)
- Emergency Medicine (398)
- Epidemiology (12205)
- Forensic Medicine (10)
- Gastroenterology (756)
- Genetic and Genomic Medicine (4079)
- Geriatric Medicine (387)
- Health Economics (679)
- Health Informatics (2636)
- Health Policy (1000)
- Hematology (362)
- HIV/AIDS (849)
- Medical Education (399)
- Medical Ethics (109)
- Nephrology (433)
- Neurology (3856)
- Nursing (209)
- Nutrition (573)
- Oncology (2015)
- Ophthalmology (584)
- Orthopedics (240)
- Otolaryngology (304)
- Pain Medicine (250)
- Palliative Medicine (75)
- Pathology (472)
- Pediatrics (1113)
- Primary Care Research (449)
- Public and Global Health (6509)
- Radiology and Imaging (1395)
- Respiratory Medicine (870)
- Rheumatology (402)
- Sports Medicine (342)
- Surgery (442)
- Toxicology (52)
- Transplantation (185)
- Urology (165)